Compare ARK Genomic Revolution ETF (ARKG) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs MobilEye Global Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while MobilEye Global Inc trades at $9.48 (market cap $8.04B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | MBLY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $16.57 |
52-Week Low | $23.09 | $6.56 |
Market Cap | — | $8.04B |
Enterprise Value | — | $6.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Mobileye (MBLY) trades at $9.55, up 0.21% with a bullish technical signal. The company shows strong revenue growth ($1.89B in 2025) but significant net losses (-$392M). Recent earnings beat expectations in Q1 2026, while analysts maintain a 57.69% buy rating with a $10.36 consensus target. The stock faces pressure from negative profitability metrics but benefits from positive sentiment around its 2027 robotaxi launch plans.
MBLY presents a high-risk opportunity with transformative potential through autonomous driving technology. The upcoming robotaxi business could drive long-term growth, but current financial losses and competitive pressures require careful monitoring. Investor sentiment remains cautiously optimistic pending execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
